The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

Journal of Urology

Volumn 185, Issue 1, 2011, Pages 60-66

  Choueiri, Toni K ^a   Xie, Wanling ^a   Kollmannsberger, Christian ^c   North, Scott ^d   Knox, Jennifer J ^g   Lampard, J Geoffrey ^f   McDermott, David F ^b   Rini, Brian I ^h   Heng, Daniel Y C ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Carcinoma, renal cell; Neoplasm metastasis; Nephrectomy; Prognosis; Survival

Indexed keywords

BEVACIZUMAB; CALCIUM; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CANADA; CANCER CENTER; CYTOREDUCTIVE SURGERY; DRUG TARGETING; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78650027911     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.09.012     Document Type: Article

References (26)

1. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655
2. G.H. Mickisch, A. Garin, and H. van Poppel Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966
3. R.C. Flanigan, G. Mickisch, and R. Sylvester Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071
4. T.K. Choueiri, R.M. Bukowski, and B.I. Rini The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma Semin Oncol 33 2006 596
5. D.Y. Heng, and C. Kollmannsberger State-of-the-art treatment of metastatic renal cell carcinoma Curr Oncol 16 2009 S16
6. K.D. Courtney, and T.K. Choueiri Optimizing recent advances in metastatic renal cell carcinoma Curr Oncol Rep 11 2009 218
7. A.J. Pantuck, A.S. Belldegrun, and R.A. Figlin Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res 13 2007 693s
8. R.J. Motzer, J. Bacik, and B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289
9. T.M. Mekhail, R.M. Abou-Jawde, and G. Boumerhi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 2005 832
10. T.K. Choueiri, B. Rini, and J.A. Garcia Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma Ann Oncol 18 2007 249
11. T.K. Choueiri, J.A. Garcia, and P. Elson Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 2007 543
12. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552
13. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794
14. M.L. Fallick, D.F. McDermott, and D. LaRock Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma J Urol 158 1997 1691
15. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28: 1502.
16. A.A. van derVeldt, M.R. Meijerink, and A.J. van denEertwegh Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 14 2008 2431
17. P.M. Pierorazio, J.M. McKiernan, and T.R. McCann Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed BJU Int 100 2007 755
18. Risk MC, Lerner M, Logan T, et al. Retrospective comparison of metastatic tumor volume to primary tumor volume in patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma. Presented at the 2010 Genitourinary Cancers Symposium, abstract 395.
19. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271
20. B. Shuch, J. Said, and J.C. La Rochelle Cytoreductive nephrectomy for kidney cancer with sarcomatoid histologyis up-front resection indicated and, if not, is it avoidable? J Urol 182 2009 2164
21. W. Kassouf, R. Sanchez-Ortiz, and P. Tamboli Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology J Urol 178 2007 1896
22. R.A. Gatenby, E.T. Gawlinski, and C.M. Tangen The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy Cancer Res 62 2002 5218
23. T. Tatsumi, C.J. Herrem, and W.C. Olson Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma Cancer Res 63 2003 4481
24. K. Fujikawa, Y. Matsui, and K. Miura Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy J Urol 164 2000 673
25. G. Dadian, P.G. Riches, and D.C. Henderson Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy Br J Urol 74 1994 15
26. T. Klatte, M. Bohm, and T. Nelius Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma BJU Int 100 2007 209